Prime Bio

What Prime Bio does

Prime Bio, Inc. is a privately held US specialty biotechnology firm founded in 1998 and headquartered in North Dartmouth, Massachusetts. The company focuses on the synthesis, detection, and application of botulinum neurotoxins, operating a catalog of research reagents (toxoids, polyclonal rabbit IgG antibodies targeting serotypes A, B, and E, and HIS-tagged recombinant proteins such as light chains and Hn-33 fragments) alongside a suite of contract research services covering toxin analysis, cell-based assays for drug toxicity and mechanistic evaluation, bioconjugation, and bespoke assay development. Its underlying technology stack draws on protein chemistry, molecular biology, cell biology, and molecular imaging, with experienced scientists performing contract research engagements directly for clients.

The company's commercial model is a sales-led, quote-based motion distributing research reagents in unit quantities (e.g., Toxoid A at $710 per 0.1 mg, Toxoid E at $1,360 per 0.1 mg, polyclonal antibodies at $2,600 per 1 mg, recombinant proteins at $520-$5,720 per SKU) alongside custom service engagements. Customers span US universities, federal agencies (DoD, FDA, CDC, NIH), and leading industrial companies, with global reach signaled by direct-sales distribution and a recently granted patent in South Africa.

Prime Bio's strategic posture is that of a long-tenured niche specialist. It holds US and South African patents (granted November 2024) on a Tetanus Vaccine Platform that signals an emerging pivot from pure reagent supply toward vaccine platform IP, and lists affiliations with the Institute of Advanced Sciences, Omni Array Biotechnology, and Nanobiosym. The firm operates without disclosed outside funding, M&A activity, or management turnover, indicating a stable, owner-managed specialty reagent and services business rather than a venture-backed scale-up.

Name

Prime Bio

Legal name

Prime Bio, Inc.

Website

https://primebio.net

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

11–50 employees

Short description

Prime Bio is a privately held US biotech founded in 1998 that supplies botulinum neurotoxin research reagents (toxoids, polyclonal antibodies, recombinant proteins) and contract research services to universities, federal agencies (DoD, FDA, CDC, NIH), and industrial customers.

Ownership category

akta.pro rank

Product category

Biotechnology Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Cell-Based & Potency Assays (Bioassays) (HLAGADAH)

akta.pro secondary industries

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Clinical Research & Trial Central Laboratories (HLAFAMAL)

Keywords

• Botulinum neurotoxin research
• Polyclonal antibody production
• Recombinant protein manufacturing
• Contract research services
• Toxin analysis services

Headquarters

HQ city

North Dartmouth

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Biotech Product Sales: Sale of specialized research products including toxoids, polyclonal antibodies, and recombinant proteins for botulinum neurotoxin research. Products are sold in unit quantities (0.1mg, 1mg) with pricing based on product type.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Prime Bio, Inc. develops, manufactures, and sells specialized botulinum neurotoxin research products — toxoids, polyclonal rabbit IgG antibodies, and recombinant HIS-tagged proteins — and provides related contract research services including toxin analysis, cell-based assays, bioconjugation, and custom research projects. The company serves research institutions, government laboratories, and industrial pharmaceutical and biotechnology companies with deep expertise in protein chemistry, cell biology, molecular biology, and molecular imaging.

Product overview

Prime Bio, Inc. offers a specialized portfolio of botulinum neurotoxin-related products and research services. The product portfolio comprises three main categories: (1) Toxoids including Type A Toxin Complex (BB101), Toxoid A (BB205), Toxoid E (BB206), and Tetanus Toxoid (BB210) - deactivated neurotoxin complexes used for research; (2) Polyclonal Rabbit IgG Antibodies including 13 distinct products (BB257-BB280) targeting various neurotoxin types A, B, and E as well as light chain, heavy chain, and hemagglutinin components; and (3) Recombinant proteins including LCA (BB103), LCB (BB112), LCE (BB120), Hn-33 Type A (BB107R), and DRBONT/A (BB102R) - HIS Tagged recombinant proteins. The company also provides four research services: Contract Research, Toxin Analysis, Cell-based Assays, and Bioconjugation.

Differentiator

Problem solved

Functional benefit

Products and services

• Type A Toxin Complex (BB101) Clostridium Botulinum Type A Neurotoxin Complex purified from native culture, sold as a research reagent for botulinum neurotoxin studies.
• Toxoid A (BB205) Deactivated Clostridium botulinum Type A Neurotoxin Complex exposed to formalin treatment to remove activity; mixture of all complexing proteins with the neurotoxin, used as a research reagent.
• Toxoid E (BB206) Deactivated Clostridium botulinum Type E Neurotoxin Complex sold as a research reagent.
• Tetanus Toxoid (BB210) Deactivated Tetanus Neurotoxin exposed to formalin treatment; derived from inactive recombinant neurotoxin, HIS Tagged from E. coli, sold as a research reagent.
• a-TANC IgG (BB257) Type A Neurotoxin Complex Toxoid IgG, polyclonal rabbit antibodies, purified polyclonal IgG raised against Clostridium botulinum Type A Neurotoxin Complex toxoid.
• a-NTA IgG (BB258) Anti-Neurotoxin Type A Toxoid IgG, polyclonal rabbit antibodies, purified polyclonal IgG raised against Clostridium botulinum Type A Neurotoxin toxoid.
• a-LCA IgG (BB259) Anti-Type A Light Chain Toxoid IgG, polyclonal rabbit antibodies, purified polyclonal IgG raised against Clostridium botulinum Type A Neurotoxin Light Chain Toxoid.
• a-HCA IgG (BB260) Anti-Type A Heavy Chain Toxoid IgG, polyclonal rabbit antibodies, purified polyclonal IgG raised against Clostridium botulinum Type A Neurotoxin Heavy Chain Toxoid.
• a-HCQ IgG (BB2601) Anti-Type A Heavy Chain C-terminal quarter fragment Toxoid IgG, polyclonal rabbit antibodies, purified polyclonal IgG raised against Clostridium botulinum Type A Neurotoxin Heavy Chain C-Terminal 25kDa terminal quarter fragment Toxoid.
• a-Hn33A IgG (BB261) Anti-Hemagglutinin Type A Toxoid IgG, polyclonal rabbit antibodies, purified polyclonal IgG raised against Clostridium botulinum Type A Hemagglutinin Toxoid.
• a-TBNC IgG (BB262) Type B Neurotoxin Complex Toxoid IgG, polyclonal rabbit antibodies, purified polyclonal IgG raised against Clostridium botulinum Type B Neurotoxin Complex Toxoid.
• a-NTB IgG (BB263) Anti-Neurotoxin Type B Toxoid IgG, polyclonal rabbit antibodies, purified polyclonal IgG raised against Clostridium botulinum Type B Neurotoxin Toxoid.
• a-LCB IgG (BB264) Anti-Type B Light Chain Toxoid IgG, polyclonal rabbit antibodies, purified polyclonal IgG raised against Clostridium botulinum Type B Neurotoxin Light Chain Toxoid.
• a-TENC IgG (BB266) Type E Neurotoxin Complex Toxoid IgG, polyclonal rabbit antibodies, purified polyclonal IgG raised against Clostridium botulinum Type E Neurotoxin Complex Toxoid.
• a-NTE IgG (BB267) Anti-Neurotoxin Type E Toxoid IgG, polyclonal rabbit antibodies, purified polyclonal IgG raised against Clostridium botulinum Type E Neurotoxin Toxoid.
• a-LCE IgG (BB268) Anti-Neurotoxin Type E Light Chain Toxoid IgG, polyclonal rabbit antibodies, purified polyclonal IgG raised against Clostridium botulinum Type E Neurotoxin Light Chain Toxoid.
• a-NTT IgG (BB280) Anti-Tetanus Neurotoxin Toxoid IgG, polyclonal rabbit antibodies, purified polyclonal IgG raised against Clostridium tetanae Neurotoxin Toxoid.
• LCA (BB103) Botulinum Neurotoxin Light Chain Type A, Recombinant HIS Tagged protein sold as a research reagent.
• LCB (BB112) Botulinum Neurotoxin Light Chain Type B, Recombinant HIS Tagged protein sold as a research reagent.
• LCE (BB120) Botulinum Neurotoxin Light Chain Type E, Recombinant HIS Tagged protein sold as a research reagent.
• Hn-33 Type A (BB107R) Recombinant Hn-33 Type A, 33 kDa protein with HIS Tag sold as a research reagent.
• DRBONT/A (BB102R) Detoxified Recombinant Botulinum Neurotoxin Type A Mutant, inactive protein with HIS Tag sold as a research reagent.
• Contract Research Research services performed by Prime Bio's experienced scientists trained in cell biology, molecular biology, protein chemistry, and molecular imaging, covering assay development, cellular binding and translocation studies, molecular imaging, and other botulinum neurotoxin-related projects.
• Toxin Analysis One-stop botulinum toxin analysis services including toxin quantitation, toxin activity measurement, and toxin type identification.
• Cell-based Assays Services for drug toxicity testing and mechanistic evaluation of various types of compounds.
• Bioconjugation Bioconjugation services enabling conjugation of various functional molecules to proteins.

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Three partnerships are on record, tiered minor.

• Institute of Advanced SciencesminorOthers · 12 November 2024Listed as an important link on Prime Bio's website, indicating a relationship with a related research organization.
• Omni Array BiotechnologyminorOthersListed as an important link on Prime Bio's website, suggesting affiliation with another biotechnology company.
• NanobiosymminorOthersListed as an important link on Prime Bio's website, indicating connection with a nanotechnology/biotechnology company.

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Abcam (Danaher): Abcam, owned by Danaher, is one of the world's largest research antibody suppliers with deep catalog breadth and a global e-commerce platform. It competes with Prime Bio's polyclonal antibody business through scale, brand recognition, and online purchasing convenience that Prime Bio's quote-based model cannot match.
• Lonza Group: Lonza is a global CDMO/CRO with bioconjugation, cell-based assay, and biological product manufacturing capabilities. Its bioconjugation and biologics testing services directly overlap with Prime Bio's service offerings, although Lonza serves commercial-scale biopharma while Prime Bio serves research-scale users.
• Bio-Rad Laboratories: Bio-Rad (NYSE: BIO) supplies life-science research products including antibodies, proteins, and clinical-research instrumentation. It is a broader incumbent whose research-reagent catalog and global sales reach overlap with Prime Bio's products, particularly for polyclonal antibodies used in toxin detection workflows.
• Cell Signaling Technology: Cell Signaling Technology is a leading private supplier of high-quality antibodies and recombinant proteins for signal-transduction and neuroscience research. It is comparable to Prime Bio as a privately held specialty reagent provider, although at much greater scale and broader target coverage.
• Bio-Techne: Bio-Techne (NASDAQ: TECH) is a large life-science tools company selling recombinant proteins, antibodies, and assay kits across thousands of targets, including botulinum-related reagents. It competes with Prime Bio through broader catalog, global distribution, and platform credibility rather than niche specialization.
• Charles River Laboratories: Charles River Laboratories (NYSE: CRL) is a large CRO offering cell-based assay services, biologics safety testing, and research products. It is comparable to Prime Bio on the contract-research and cell-based assay services side, but at significantly greater scale and broader therapeutic coverage.
• Santa Cruz Biotechnology: Santa Cruz Biotechnology is a large research-reagent supplier offering polyclonal and monoclonal antibodies and related biochemicals. It overlaps with Prime Bio in research antibodies for niche targets and competes on breadth and price in academic purchasing channels.

Direct peers

• List Biological Laboratories: List Biological Laboratories is a closely comparable niche supplier of bacterial toxins, toxoids, antibodies, and recombinant proteins for research use, including a substantial botulinum neurotoxin catalog. It overlaps directly with Prime Bio on product type (toxoids, antitoxin antibodies), customer base (government and academic labs), and specialty unit-pricing model.
• Metabiologics: Metabiologics provides purified botulinum neurotoxins, recombinant proteins, and related research reagents specifically for clostridial toxin research. It is one of the few small specialists competing with Prime Bio in the same botulinum-focused reagent niche.
• Toxogen GmbH: Toxogen is a contract research organization specializing in botulinum neurotoxin assays, cell-based potency testing, and custom antibody services — directly mirroring Prime Bio's cell-based assay, toxin analysis, and contract research offerings for the same buyer set.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/primebio

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Prime Bio